Certara

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Certara surpasses revenue expectations, eyes global expansion and innovation

Certara's strong financial performance in Q4 2022 and exceeding revenue guidance for the full year underscore the company's growth trajectory and market positioning.
With a focus on software, biosimulation services, and global expansion, Certara is poised for continued success in 2023 and beyond.
The company's proactive engagement with regulatory bodies, strategic acquisitions, and partnerships signal a commitment to innovation and sustainable growth.

Certara reports robust Q1 earnings driven by biosimulation strength

Certara's Q1 2023 showcased solid financial performance, particularly in software and biosimulation services. Despite challenges in deal closure times and subscription model impact, the company remains optimistic about future growth opportunities.

Certara reports solid Q2 earnings, eyes growth through AI integration

Certara's Q2 performance showed growth in both software and services revenue, with adjusted EBITDA at $32.4 million.
The company faces challenges from cautious spending and slow recovery in regulatory business but remains optimistic about long-term industry potential.
Strengths include acquisitions enhancing AI capabilities, focus on accelerating projects, and expanding key offerings.
Opportunities lie in integrating AI, driving growth in biosimulation services, and aiming for higher growth in 2024.

Certara reports stable Q3 performance, eyes growth in biosimulation and AI

Certara's Q3 performance showed revenue growth driven by software, despite challenges in services revenue.
The company remains confident in its strategies and outlook for growth, focusing on biosimulation and AI integration.
While facing uncertainties in closing AI product deals, Certara sees opportunities in market demand and long-term growth.
Analysts' inquiries during the call highlighted areas of concern but also underscored Certara's strengths and potential for expansion.

Certara reports steady revenue growth, eyes software investments for 2024

Certara's Q4 2023 performance reflects a mixed revenue picture with software revenue growth offsetting a decline in services revenue, while the company maintains a strong financial position.
Strategic acquisitions, growth initiatives in key markets, and a focus on operational efficiency present avenues for Certara to drive future growth and enhance market competitiveness.
Challenges lie in balancing revenue streams, managing margin pressures from investments, and navigating market uncertainties, requiring strategic decision-making and operational agility.
Overall, Certara's outlook for 2024 is optimistic, underpinned by confidence in growth drivers, strategic acquisitions, and a commitment to innovation and market expansion.

Certara reports solid Q1 performance and eyes revenue acceleration

Certara's Q1 performance reflects growth in software revenue and steady services revenue, with a focus on operational efficiency and strategic goals for 2024.
Challenges include seasonality in services bookings and the need for further restructuring, while opportunities lie in potential revenue acceleration and market dynamics.
Overall, Certara remains optimistic for the year ahead, maintaining revenue and EPS guidance for 2024 and aiming for margin improvement in the second half.

Certara reports Q2 revenue growth, acquires Chemaxon for innovation

Certara's Q2 performance showed mixed results with revenue growth driven by Software but offset by a decline in Services, while bookings and adjusted EBITDA demonstrated positive momentum.
The company's strategic strengths lie in recent acquisitions, product innovations, and a focus on software and AI investments to drive future growth and profitability.
Challenges include addressing declines in the Services segment, improving performance with Tier 1 customers, and managing operational costs to reduce net losses.
Opportunities for Certara include meeting full-year revenue guidance, leveraging software and AI investments for industry leadership, and expanding market presence through recent acquisitions and product releases.

Certara reports strong Q3 earnings, focuses on biosimulation growth

Certara's Q3 performance was strong, driven by revenue growth and strategic investments in software and commercial reach.
While facing challenges in the regulatory services market, Certara is focused on leveraging opportunities from the Chemaxon acquisition and uniting R&D and sales efforts for sustainable growth.
The company's financial position is robust with healthy cash reserves, but managing debt levels and maintaining margins in regulatory services remain key challenges.
Certara's outlook for 2024 is positive, with updated guidance indicating revenue of $380-385 million and adjusted EBITDA of $120-124 million.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.

CRISPR Therapeutics

Incyte

Morphosys AG - ADR

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

MINISO Group Holding

PDF Solutions

Ritchie Bros. Auctioneers

MINISO Group Holding Limited (NYSE: MNSO), PDF Solutions Inc. (NASDAQ: PDFS), and Certara Inc. (NASDAQ: CERT) are relatively unknown stocks currently showing strong price momentum.

Are These 3 Small Momentum Stocks Setting Up Big Gains?

Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year.

Is Certara (CERT) Outperforming Other Medical Stocks This Year?

Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?

New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.

A.I. Coming to Certara's D360 Scientific Informatics Software

Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies

Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types

Certara, Inc. (NASDAQ:CERT ) Q4 2022 Results Conference Call March 1, 2023 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer Andrew Schemick - Chief Financial Officer Conference Call Participants David Windley - Jefferies Vikram Purohit - Morgan Stanley Luke Sergott - Barclays Dan Leonard - Credit Suisse Joy Zhang - SVB Securities Operator Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2022 Earnings Conference Call.

Certara, Inc. (CERT) Q4 2022 Earnings Call Transcript

Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Tops Q4 Earnings and Revenue Estimates

Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency

Certara Reports Fourth Quarter and Full Year 2022 Financial Results

PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023.  Mr. Schemick will transition into a newly created position as Senior Vice President, Corporate Operations and Integration, and he will be focused on supporting John's transition, and then building operational excellence as Certara continues to grow.

Certara Announces Transition Plan for Chief Financial Officer

PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healthcare Conference.

Certara to Participate in the Barclays Global Healthcare Conference

PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023

Puma Biotechnology

CERT vs. PBYI: Which Stock Is the Better Value Option?

CERT vs. PBYI: Which Stock Should Value Investors Buy Now?

Certara improves software capabilities by expanding into deep learning and data fabric Certara improves software capabilities by expanding into deep learning and data fabric

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity

Certara Announces the Completion of Arsenal Capital Partners' Investment and the Appointment of David Spaight to the Board of Directors

Unlike Schrodinger, Certara posted a profit in the last quarter. Business momentum is accelerating as backlog grows.

Why Certara Is A Buy For 2023

The company, which helps other companies in their drug development, reported strong third-quarter numbers.

Why Certara's Shares Rose 37.7% This Week

Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q3 Earnings Miss Estimates

Certara Inc. (NASDAQ:CERT ) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO Andrew Schemick - CFO Conference Call Participants Dave Windley - Jefferies Max Smock - William Blair Luke Sergott - Barclays Joe Vruwink - Baird Wolf Chanoff - Bank of America Lu Li - Credit Suisse Operator Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2022 Earnings Conference Call.

Certara Inc. (CERT) Q3 2022 Earnings Call Transcript

Biosimulation software and services fuel third quarter growth Biosimulation software and services fuel third quarter growth

Certara Reports Third Quarter 2022 Financial Results

Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares

Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

The PMDA enters 9th consecutive year of using Certara's software The PMDA enters 9th consecutive year of using Certara's software

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Software for Evaluating Regulatory Submissions

PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022

Certara Inc (NASDAQ: CERT) shares are trading lower by 15.40% to $17.08 Friday morning after the company announced a secondary offering of 7 million shares of common stock. What Else?

Here's Why Certara Stock Is Falling Friday

PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) (“Certara”), a global leader in biosimulation, today announced the sale by certain stockholders (the “Selling Stockholders”), including EQT Avatar Parent L.P., in an underwritten secondary offering of 7,000,000 shares of common stock of Certara pursuant to a registration statement filed by Certara with the U.S. Securities and Exchange Commission (the “SEC”). In connection with the offering, the Selling Stockholders have granted the underwriter a 30-day option to purchase up to 1,050,000 additional shares. No shares are being sold by Certara. The Selling Stockholders will receive all of the proceeds from this offering. The last reported sale price of Certara's common stock on August 11, 2022 was $20.19. Closing of the offering is expected to occur on or about August 16, 2022, subject to customary closing conditions.

News for Certara Stock (CERT)